RePHILL: protocol for a randomised controlled trial of pre‐hospital blood product resuscitation for trauma

• Published in: Transfusion medicine (Oxford, England) England), 2018-10, Vol.28 (5), p.346-356
• Main Authors: Smith, I. M., Crombie, N., Bishop, J. R., McLaughlin, A., Naumann, D. N., Herbert, M., Hancox, J. M., Slinn, G., Ives, N., Grant, M., Perkins, G. D., Doughty, H., Midwinter, M. J.
• Format: Article
• Language: English
• Subjects: Blood Component Transfusion; blood transfusion; Clinical Trials, Phase III as Topic; Crystalloid Solutions - administration & dosage; emergency medical services; Female; haemorrhage; Humans; Male; Multicenter Studies as Topic; randomised controlled trial; Randomized Controlled Trials as Topic; Resuscitation; United Kingdom; wounds and injuries; Wounds and Injuries - therapy
• ISSN: 0958-7578; 1365-3148; 1365-3148
• DOI: 10.1111/tme.12486

SUMMARY Objectives To describe the ‘Resuscitation with Pre‐HospItaL bLood products’ trial (RePHILL) – a multi‐centre randomised controlled trial of pre‐hospital blood product (PHBP) administration vs standard care for traumatic haemorrhage. Background PHBP are increasingly used for pre‐hospital trauma resuscitation despite a lack of robust evidence demonstrating superiority over crystalloids. Provision of PHBP carries additional logistical and regulatory implications, and requires a sustainable supply of universal blood components. Methods RePHILL is a multi‐centre, two‐arm, parallel group, open‐label, phase III randomised controlled trial currently underway in the UK. Patients attended by a pre‐hospital emergency medical team, with traumatic injury and hypotension (systolic blood pressure